Lineage Cell Therapeutics
LCTX
130 hedge funds and large institutions have $176M invested in Lineage Cell Therapeutics in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 12 closing their positions.
495% more call options, than puts
Call options by funds: $226K | Put options by funds: $38K
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
6% more funds holding
Funds holding: 123 → 130 (+7)
4% more capital invested
Capital invested by funds: $170M → $176M (+$6.71M)
0.7% more ownership
Funds ownership: 44.14% → 44.84% (+0.7%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$7.76M |
| 2 |
Millennium Management
New York
|
+$5.82M |
| 3 |
AC
Armistice Capital
New York
|
+$5.37M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.87M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$634K |
| 2 |
Renaissance Technologies
New York
|
-$472K |
| 3 |
Goldman Sachs
New York
|
-$454K |
| 4 |
Two Sigma Investments
New York
|
-$298K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$294K |
LCTX Hedge Fund Activity: Q1 2026 in Review
130 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2026, worth a combined $176M — up 4% from $170M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LCTX positions and 12 closed out — a net gain of 12 holders — while 37 added to existing stakes and 26 trimmed.
The largest buyer was Fifth Third Bancorp, opening a new position worth an estimated $7.76M. The largest seller was Citadel Advisors, cutting an estimated $634K.
- 130 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2026, up from 123 in Q4 2025.
- Funds reported $176M of Lineage Cell Therapeutics stock for Q1 2026, up 4% quarter-over-quarter.
- 24 funds opened new Lineage Cell Therapeutics positions in Q1 2026 and 12 closed out, a net change of +12 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2026 was Fifth Third Bancorp, an estimated $7.76M added.
- The largest Lineage Cell Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $634K sold.
Based on aggregated 13F filings for Q1 2026.